Prescient Therapeutics initiates first US site for Phase 2a trial of PTX-100 in CTCL
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
The first United States clinical trial site for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF)’s Phase 2a study...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...
Prescient Therapeutics Ltd has kicked off its Phase 2a clinical trial evaluating PTX-100 for relapsed...
Prescient Therapeutics Ltd has received Fast Track Designation from the United States Food and Drug...
Prescient Therapeutics Ltd has appointed Melanie Farris as an independent non-executive director, further strengthening its...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.